Clinical Development Program Utilizing Xenomics' DNA-Based Diagnostic Technology is Ranked Best in Europe
European Consortium led By Xenomics' collaborative venture with leading European research center prepares for euro 2 million funding of tuberculosis clinical program.
RCP Diagnostics Licenses Its Protein Marker to Biomarker Technologies
Biomarker will use the RCP marker only for the diagnosis of breast cancer.
J. Brian Munroe Elected President and Chairman of Personalized Medicine Coalition
Newly appointed vice president of WellPoint brings important payer constituency into coalition.
GeneGo and XB TransMed Provide Integrated Solutions to the Translational Medicine Market
XB-BIS integration with the MetaCore™ permits the user to integrate back and forth between expanding knowledge and enhanced application.
Scientists Develop Concept with Potential to Help Predict how Individuals may Respond to Drugs
The method is expected to be synergistic with existing pharmacogenomic approaches.
Dalton Pharma Services Announces Completion of its GMP Oligonucleotide Manufacturing Facility
Building on its 17 year history in oligonucleotide manufacture and analysis, Dalton can now use its expertise in synthesis and manufacturing of antisense oligonucleotides.
bmd Obtains FDA Approval for Four new FIDIS™ Diagnostic Kits for Autoimmune Diseases
Approval of FIDIS Connective 10, Vasculitis, Celiac IgC and Celiac IgA will boost bmd's penetration of the North American market
Expanded Access Program for Rexin-G™ Provides Genetic Medicine to Cancer Patients
The Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients.
Industry Leaders and Investors Explore Better Business Models for the 'New Diagnostics' at Bio 2006
Experts will debate business models to support the growing potential of molecular diagnostics during a kick-off panel at BIO 2006.
Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine
Third Wave will accelerate and expand the development of high-value clinical products for the Japanese molecular diagnostic market.